CD4 and inflammatory bowel disease: To investigate the effects of systemic CM4620 treatment on IBD progression and severity, we injected lymphopenic Rag1−/− mice with naïve CD4+ T cells from wildtype mice followed by gavage of host mice with CM4620 or vehicle (Fig 7D).